Rituximab therapy to prevent relapse in chronic relapsing Thrombotic Thrombocytopenic Purpura (TTP) in a child

Somasundaram Jayabose, Julie Dunbar, Theodore S. Nowicki, Oya Tugal, Mehmet Fevzi Ozkaynak, Claudio Sandoval

Research output: Contribution to journalArticle

17 Scopus citations

Abstract

Our patient first developed thrombotic thrombocytopenic purpura (TTP) at age 10 years with an initial platelet count of 10,000/μL. She achieved remission with plasmapheresis (PE), but suffered 2 relapses in the next 2 years, each approximately 1 year from PE, with ADAMTS13 levels of <5%. Early in her third remission, with vincristine (weekly ×-4 doses) and prednisone (for 2 weeks) her ADAMTS13 increased to 99% in 24 weeks, but decreased to <4% in the next 38 weeks. After 4 weekly doses of rituximab (375 mg/m2), her ADAMTS13 level reached 101% in 9 weeks and has remained consistently above 97% on bimonthly monitoring for more than a year. She remains in continuous clinical and hematologic remission with an ADAMTS13 level of 108% at 60 weeks from rituximab therapy and 124 weeks from her second relapse. This case report suggests that monitoring ADAMTS13 level at regular intervals in recurrent TTP may help us identify patients at risk for further relapse; and such a relapse may be prevented, or at least delayed with timely rituximab therapy, thus reducing morbidity from relapsed TTP and its treatment.

Original languageEnglish (US)
Pages (from-to)167-172
Number of pages6
JournalPediatric Hematology and Oncology
Volume28
Issue number2
DOIs
StatePublished - Mar 1 2011
Externally publishedYes

Keywords

  • TTP
  • refractory
  • relapsing
  • rituximab
  • thrombotic thrombocytopenic purpura

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Rituximab therapy to prevent relapse in chronic relapsing Thrombotic Thrombocytopenic Purpura (TTP) in a child'. Together they form a unique fingerprint.

  • Cite this